RANCHO CORDOVA, Calif., March 2 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading developer and supplier of products that process and store adult stem cells, announced today that products derived from its Intellectual Property have been used to collect, process and store stem cells from cord blood in more than one million procedures since the products were introduced a decade ago. Cord blood stem cells have been used to reconstitute the blood cell forming marrow of patients undergoing treatment for leukemia and lymphoma. Cord blood is also being used in studies regarding treatment for more than 70 genetic diseases and most recently, cerebral palsy.
"The collection and processing of stem cells from cord blood utilizing these products has increased dramatically over the past decade, rising from 5,000 units in 1999 to more than 250,000 units in 2008," said Matthew Plavan, Chief Executive Officer of ThermoGenesis Corp.
These products include:
"We believe that the ongoing research regarding the therapeutic benefits of stem cells and the likely expansion of financial support for stem cell programs will mandate greater activity in the collection, processing, freezing and storage of cord blood stem cell units in the future," Plavan said.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
ThermoGenesis Corp. Web site:http://www.thermogenesis.com Contact: Investor Relations +1-916-858-5107, or email@example.com
|SOURCE ThermoGenesis Corp.|
Copyright©2009 PR Newswire.
All rights reserved